Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024 16:05 ET
|
Artiva Biotherapeutics, Inc.
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
November 11, 2024 16:05 ET
|
Artiva Biotherapeutics, Inc.
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
October 22, 2024 16:05 ET
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024 16:05 ET
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 29, 2024 16:05 ET
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
July 18, 2024 19:08 ET
|
Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering